| Characteristic |
Overall, N = 114 |
G12D, N = 38 |
Other or wild, N = 76 |
p-value |
| PD_L1_1, n (%) |
|
|
|
0.3 |
| Negative |
76 (67%) |
23 (61%) |
53 (70%) |
|
| Positive |
38 (33%) |
15 (39%) |
23 (30%) |
|
| PD_L1_2, n (%) |
|
|
|
0.3 |
| Negative |
82 (72%) |
25 (66%) |
57 (75%) |
|
| Positive |
32 (28%) |
13 (34%) |
19 (25%) |
|
| PD_L1_3, n (%) |
|
|
|
0.5 |
| Negative |
94 (82%) |
30 (79%) |
64 (84%) |
|
| Positive |
20 (18%) |
8 (21%) |
12 (16%) |
|
| Tumor purity, Mean (SD) |
0.49 (0.19) |
0.44 (0.17) |
0.52 (0.20) |
0.061 |
| Gender, n (%) |
|
|
|
0.7 |
| |
1 (0.9%) |
0 (0%) |
1 (1.3%) |
|
| Female |
38 (33%) |
11 (29%) |
27 (36%) |
|
| Male |
75 (66%) |
27 (71%) |
48 (63%) |
|
| Patient Age, Mean (SD) |
60.08 (9.07) |
61.84 (8.56) |
59.20 (9.24) |
0.2 |
| TMB value, Mean (SD) |
2.66 (2.16) |
2.62 (1.57) |
2.68 (2.42) |
0.6 |
| MSI score, Mean (SD) |
7.73 (8.89) |
8.48 (9.08) |
7.35 (8.83) |
0.5 |
| KRAS_Type, n (%) |
|
|
|
<0.001 |
| G12X |
88 (77%) |
38 (100%) |
50 (66%) |
|
| Other or wild |
26 (23%) |
0 (0%) |
26 (34%) |
|
| HRR Mutation, n (%) |
|
|
|
0.7 |
| 0 |
97 (85%) |
34 (89%) |
63 (83%) |
|
| 6.666666667 |
15 (13%) |
4 (11%) |
11 (14%) |
|
| 13.33333333 |
2 (1.8%) |
0 (0%) |
2 (2.6%) |
|
| MMR Mutation, n (%) |
|
|
|
0.5 |
| 0 |
107 (94%) |
35 (92%) |
72 (95%) |
|
| 20 |
6 (5.3%) |
2 (5.3%) |
4 (5.3%) |
|
| 80 |
1 (0.9%) |
1 (2.6%) |
0 (0%) |
|
| HRR, n (%) |
|
|
|
0.4 |
| Mut |
17 (15%) |
4 (11%) |
13 (17%) |
|
| Wild |
97 (85%) |
34 (89%) |
63 (83%) |
|